Friday - March 13, 2026

Category Archives: Pharmaceuticals & Biotech

Celiac Disease Drug Development Advances as 25+ Companies Progress 30+ Therapies Across Clinical Trials, Reveals DelveInsight Pipeline Analysis

Celiac Disease pipeline Key companies actively involved in the cec disease drug development landscape include Takeda, Anokion SA, Mozart Therapeutics, AMYRA Biotech AG, Equillium Bio., Chugai Pharmaceutical Co., Ltd., Calypso Biotech, ImmunogenX Inc., Amgen Inc., and several other emerging biotechnology … Continue reading →

Sapropterin (KUVAN) Comprehensive Forecast on the Accelerating Market Growth for Phenylketonuria (PKU) and BH4 Deficiency by 2034

Sapropterin Sales Forecast, and Market Size Analysis – 2034 DelveInsight Releases In-Depth Drug Insight and Market Forecast Report on Sapropterin (developed and marketed by BioMarin Pharmaceutical Inc.) Sales Analysis Across the 7 Major Markets Through 2034 DelveInsight, a leading healthcare-focused … Continue reading →

Presbyopia Pipeline Insight Expands as 10+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | Glaukos Corporation, Orasis Pharmaceuticals, Novartis, Cellix Bio

Presbyopia – Pipeline Insight, 2026 DelveInsight’s “Presbyopia – Pipeline Insight, 2026” report provides comprehensive insights about several companies, including Glaukos Corporation, Orasis Pharmaceuticals, Novartis, Cellix Bio, Visus Therapeutics, AbbVie, Vyluma, Lenz Therapeutics, Ocuphire Pharma, JIXING Pharmaceuticals, Eyenovia, and others, developing … Continue reading →

Diabetic Macular Edema Treatment Pipeline Shows Strong Momentum as 45+ Pharma Companies in the Race | DelveInsight

DelveInsight’s “Diabetic Macular Edema Pipeline Insight 2026” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Diabetic Macular Edema pipeline landscape. It covers the Diabetic Macular Edema pipeline drug profiles, including clinical and nonclinical stage products. It … Continue reading →

Diabetic Retinopathy Clinical Trial Pipeline Expands as 50+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s, “Diabetic Retinopathy Pipeline Insights 2026” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the Diabetic Retinopathy pipeline landscape. It covers the Diabetic Retinopathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

Dry Eye Disease Clinical Trial Pipeline Shows Potential with Active Contributions from 50+ Key Companies | DelveInsight

DelveInsight’s “Dry Eye Disease Pipeline Insight 2026” report provides comprehensive insights about 50+ companies and 60+ pipeline drugs in the Dry Eye Disease pipeline landscape. It covers the Dry Eye Disease pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading →

Radial Artery Compression Devices Market to Reach USD 450.97 Million by 2032 at a CAGR of 7.10%, Driven by Rising Transradial Procedures and Cardiovascular Disease Burden | DelveInsight

Radial Artery Compression Devices Market The leading Radial Artery Compression Devices companies operating in the market include Terumo Corporation, Abbott, Teleflex Incorporated, Lepu Medical Technology (Beijing) Co. Ltd., TZ Medical Inc., Merit Medical Systems, Inc., Medtronic, Smiths Medical, Advanced Vascular … Continue reading →

Cystic Fibrosis Clinical Trial Pipeline Accelerates as 75+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s, “Cystic fibrosis Pipeline Insight, 2026” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Cystic fibrosis pipeline landscape. It covers the Cystic Fibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

Cyclin-Dependent Kinase Inhibitor Clinical Trial Pipeline Gains Momentum: 45+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s, “Cyclin-Dependent Kinase Inhibitor Pipeline Insights 2026” report provides comprehensive insights about 45+ companies and 52+ pipeline drugs in Cyclin-Dependent Kinase Inhibitor pipeline landscape. It covers the Cyclin-Dependent Kinase Inhibitor pipeline drug profiles, including clinical and nonclinical stage products. It … Continue reading →